Moderna (NASDAQ: MRNA ) stock is rising higher on Tuesday following the release of data from a Phase 2B cancer vaccine clinical trial. Moderna is currently testing its cancer vaccine alongside Merck &

Moderna CEO Stéphane Bancel on promising new data for mRNA cancer vaccine

08:50am, Tuesday, 13'th Dec 2022

Moderna CEO Stéphane Bancel joins CNBC's 'Squawk Box' to discuss promising new data surrounding its experimental cancer vaccine in development with Merck.

Merck, Moderna say mRNA vaccine and Keytruda lowers the risk of death in melanoma patients

07:34am, Tuesday, 13'th Dec 2022

Merck & Co. Inc. MRK, +0.17% and Moderna Inc. MRNA, -6.89% said Tuesday that their experimental mRNA-based cancer vaccine reduced the risk of recurrence or death when used with Merck's Keytruda in pat

Why Merck's $250 Million Investment In Moderna May Have Just Paid Off

07:00am, Tuesday, 13'th Dec 2022

Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results could spark downtrodden Moderna stock.

3 Medical Stocks With Solid Growth Drivers to Keep Track Of

10:32am, Monday, 12'th Dec 2022

Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.

PFIZER VS MODERNA; Which Pharmaceutical Is A Better Stock To Buy Now?

10:30am, Saturday, 10'th Dec 2022

Pfizer VS Moderna Third Quarter Earnings And Revenue

3 Surefire Stocks to End 2022 on a Good Note

06:00am, Saturday, 10'th Dec 2022

These stocks should help your portfolio shine now and well into the future.

FDA Approves Pfizer, Moderna's Omicron COVID Jabs in Younger Kids

12:48pm, Friday, 09'th Dec 2022

Amid a rise in seasonal respiratory illnesses in younger children across the country, the FDA broadens the label of authorized bivalent Omicron BA.4/BA.5-adapted vaccines to include children as young